LogoTestata.png

logo instagram 35x35.png  logo youtube 35x35.png logo twitter 35x35.png logo facebook 35x35.png

Didona Biagio

Chi sono

  • Specialista in Dermatologia e Venereologia.
  • Specialista in Allergologia e Immunologia Clinica.
  • Responsabile Centro per le Malattie Rare (genodermatosi, malattie bollose autoimmuni, vasculiti, malattie del connettivo).

Attività Scientifica

1. Shiitake dermatosis in a Caucasian woman.

Didona D, Mostaccioli S, Paolino G, Cantisani C, Caposiena Caro RD, Viti G, Didona B.

G Ital Dermatol Venereol. 2018 Aug;153(4):586-588. doi: 10.23736/S0392-0488.17.05591-2. No abstract available.

2. Role of the keratin 1 and keratin 10 tails in the pathogenesis of ichthyosis hystrix of Curth Macklin.

Terrinoni A, Didona B, Caporali S, Chillemi G, Lo Surdo A, Paradisi M, Annichiarico-Petruzzelli M, Candi E, Bernardini S, Melino G.

PLoS One. 2018 Apr 24;13(4):e0195792. doi: 10.1371/journal.pone.0195792. eCollection 2018.

3. The Hidradenitis Suppurativa (HS) "Multidisciplinary Unit": a rationale and practical proposal for an organised clinical approach.

Chiricozzi A, Veraldi S, Fabbrocini G, Didona B, Pasquinucci S, Micali G, Romanelli M.

Eur J Dermatol. 2018 Apr 1;28(2):274-275. doi: 10.1684/ejd.2018.3254. No abstract available.

4. Biologics for pityriasis rubra pilaris treatment: a review of the literature.

Napolitano M, Abeni D, Didona B.

J Am Acad Dermatol. 2018 Mar 30. pii: S0190-9622(18)30490-0. doi: 10.1016/j.jaad.2018.03.036. [Epub ahead of print] Review.

5. Hereditary palmoplantar keratodermas. Part I. Non-syndromic palmoplantar keratodermas: classification, clinical and genetic features.

Guerra L, Castori M, Didona B, Castiglia D, Zambruno G.

J Eur Acad Dermatol Venereol. 2018 May;32(5):704-719. doi: 10.1111/jdv.14902. Epub 2018 Mar 24. Review.

6. Hereditary palmoplantar keratodermas. Part II: syndromic palmoplantar keratodermas - Diagnostic algorithm and principles of therapy.

Guerra L, Castori M, Didona B, Castiglia D, Zambruno G.

J Eur Acad Dermatol Venereol. 2018 Jun;32(6):899-925. doi: 10.1111/jdv.14834. Epub 2018 Mar 25. Review.

7. Wong-type dermatomyositis.

Didona D, Fania L, Didona B.

G Ital Dermatol Venereol. 2018 Feb;153(1):115-116. doi: 10.23736/S0392-0488.17.05441-4. No abstract available.

8. Paraneoplastic Pemphigus: Insight into the Autoimmune Pathogenesis, Clinical Features and Therapy.

Paolino G, Didona D, Magliulo G, Iannella G, Didona B, Mercuri SR, Moliterni E, Donati M, Ciofalo A, Granata G, Ranuzzi P, Falasca V, Calvieri S.

Int J Mol Sci. 2017 Nov 26;18(12). pii: E2532. doi: 10.3390/ijms18122532. Review.

9. Ustekinumab treatment of pityriasis rubra pilaris: A report of five cases.

Napolitano M, Lembo L, Fania L, Abeni D, Didona D, Didona B.

J Dermatol. 2018 Feb;45(2):202-206. doi: 10.1111/1346-8138.14114. Epub 2017 Oct 28.

10. Increased prevalence of diabetes mellitus in bullous pemphigoid patients during the last decade.

Fania L, Di Zenzo G, Didona B, Pilla MA, Sobrino L, Panebianco A, Mazzanti C, Abeni D.

J Eur Acad Dermatol Venereol. 2018 Apr;32(4):e153-e154. doi: 10.1111/jdv.14649. Epub 2017 Nov 7. No abstract available.

 11. Detection and characterization of IgG, IgE, and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors.

Fania L, Salemme A, Provini A, Pagnanelli G, Collina MC, Abeni D, Didona B, Di Zenzo G, Mazzanti C.

J Am Acad Dermatol. 2018 Mar;78(3):592-595. doi: 10.1016/j.jaad.2017.09.051. Epub 2017 Oct 4. No abstract available.

12. Acne fulminans following isotretinoine therapy.

Didona D, Paolino G, Cantisani C, Viti G, Caposiena Caro DR, Didona B.

G Ital Dermatol Venereol. 2017 Jul 13. doi: 10.23736/S0392-0488.17.05593-6. [Epub ahead of print] No abstract available.

13. Desmoplastic melanoma: a diagnostic challenge.

Didona D, Paolino G, Pagnanelli G, Donati M, Annessi G, Didona B.

G Ital Dermatol Venereol. 2018 Aug;153(4):577-578. doi: 10.23736/S0392-0488.17.05577-8. Epub 2017 Jul 11. No abstract available.

14. Lack of K140 immunoreactivity in junctional epidermolysis bullosa skin and keratinocytes associates with misfolded laminin epidermal growth factor-like motif 2 of the β3 short arm.

Condorelli AG, Fortugno P, Cianfarani F, Proto V, Di Zenzo G, Didona B, Zambruno G, Castiglia D.

Br J Dermatol. 2017 May 31. doi: 10.1111/bjd.15690. [Epub ahead of print]

15. Reduced frequency of non-melanoma skin cancer in 72,739 patients with psoriasis: a retrospective study.

Paradisi A, Didona B, Tabolli S, Ricci F, Sobrino L, Panebianco A, Abeni D.

Eur J Dermatol. 2017 Aug 1;27(4):359-362. doi: 10.1684/ejd.2017.3032.

16. Dissecting cellulitis: responding to topical steroid and oral clindamycin.

Garelli V, Didona D, Paolino G, Didona B, Calvieri S, Rossi A.

G Ital Dermatol Venereol. 2017 Jun;152(3):324-325. doi: 10.23736/S0392-0488.16.05296-2. No abstract available.

17. Prevalence and incidence of hidradenitis suppurativa: an exercise on indirect estimation from psoriasis data.

Fania L, Ricci F, Sampogna F, Mazzanti C, Didona B, Pintori G, Abeni D.

J Eur Acad Dermatol Venereol. 2017 Sep;31(9):e410-e411. doi: 10.1111/jdv.14224. Epub 2017 Apr 5. No abstract available.

18. Simvastatin-associated dermatomyositis.

Fania L, Didona D, Tonanzi T, Mazzanti C, Didona B.

Dermatol Ther. 2017 Jul;30(4). doi: 10.1111/dth.12480. Epub 2017 Mar 14. No abstract available.

19. Successful use of etanercept in a case of toxic epidermal necrolysis induced by rituximab.

Didona D, Paolino G, Garcovich S, Caposiena Caro RD, Didona B.

J Eur Acad Dermatol Venereol. 2016 Oct;30(10):e83-e84. doi: 10.1111/jdv.13330. Epub 2015 Oct 1. No abstract available.

20. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M; SOLO 1 and SOLO 2 Investigators.

N Engl J Med. 2016 Dec 15;375(24):2335-2348. Epub 2016 Sep 30.

21 Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus.

 Boulard C, Duvert Lehembre S, Picard-Dahan C, Kern JS, Zambruno G, Feliciani C, Marinovic B, Vabres P, Borradori L, Prost-Squarcioni C, Labeille B, Richard MA, Ingen-Housz-Oro S, Houivet E, Werth VP, Murrell DF, Hertl M, Benichou J, Joly P; International Pemphigus Study Group.

Br J Dermatol. 2016 Jul;175(1):142-9. doi: 10.1111/bjd.14405. Epub 2016 Apr 3.

22.Vitiligo: Pathogenesis, clinical variants and treatment approaches.

Iannella G, Greco A, Didona D, Didona B, Granata G, Manno A, Pasquariello B, Magliulo G.

Autoimmun Rev. 2016 Apr;15(4):335-43. doi: 10.1016/j.autrev.2015.12.006. Epub 2015 Dec 23. Review.